Effect of zinc on regulation of insulin-like growth factor signaling in human androgen-independent prostate cancer cells

Clinica Chimica Acta

Volumn 411, Issue 3-4, 2010, Pages 172-178

  Banudevi, Sivanantham ^a   Senthilkumar, Kalimuthu ^a   Sharmila, Govindaraj ^a   Arunkumar, Ramachandran ^a   Vijayababu, Marati Radhakrishnan ^a,b   Arunakaran, Jagadeesan ^a  

^a UNIVERSITY OF MADRAS   (India)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

AKT; Apoptosis; Cyclin D; ERK; IGF; Prostate cancer; Zinc

Indexed keywords

ANDROGEN; CYCLIN D1; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHORYLATED MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHORYLATED MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; ZINC;

APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANDROGENS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN D1; ENZYME ACTIVATION; HUMANS; INDOLES; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; SOMATOMEDINS; STAINING AND LABELING; ZINC;

EID: 72449154082     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.10.023     Document Type: Article

References (68)

1. American Cancer Society, Cancer Facts and Figures (2008). http://www.cancer.org http://www.cancer.org
2. Martin J.L., and Pattison S.L. Insulin-like growth factors binding protein-3 is regulated by dihydrotestosterone and stimulates deoxyribonucleic acid synthesis and cell proliferation in LNCaP prostatic carcinoma cells. Endocrinology 141 (2000) 401-409
3. Oosterhoff J.K., Grootegoed J.A., and Blok L.J. Expression profiling of androgen-dependent and independent LNCaP.EGF versus androgen signaling. Endocrine-Related Cancer 12 (2005) 135-148
4. Culig Z., Hobisch A., Cronauer M.V., Radmayr C., Hittmair A., Zhang J., et al. Regulation of prostatic growth and function by peptide growth factors. Prostate 28 (1996) 392-405
5. Rubben H., Bex A., and Otto T. Systemic treatment of hormone refractory prostate cancer. World T Urol 19 (2001) 99-110
6. Furstenberger G., and Senn H.J. Insulin-like growth factors and cancer. Lancet Oncol 3 (2002) 298-302
7. Fiorelli G., De Bellis A., Longo A., et al. Insulin-like growth factor-I receptors in human hyperplastic prostate tissue: characterization, tissue localization, and their modulation by chronic treatment with a gonadotropin-releasing hormone analog. J Clin Endocrinol Metab 72 (1991) 740-746
8. Cohen P., Peehl D.M., and Rosenfeld R. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 78 (1998) 554-556
9. Cohen P., Peehl D.M., Lamson G., and Rosenfeld R.G. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab 73 (1991) 401-407
10. Cohen P., Peehl D.M., Graves H.C., and Rosenfeld R.G. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol 42 (1994) 407-415
11. Burfeind P., Chernicky C.L., Rininsland F., Ilan J., and Ilan J. Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc Natl Acad Sci USA 93 (1996) 7263-7268
12. Nickerson T., Chang F., Lorimer D., Smeekens S.P., Sawyers C.L., and Pollak M. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res 61 (2001) 6276-6280
13. Pollak M.N., Schernhammer E.S., and Hankinson S.E. Insulin-like growth factors and neoplasia. Nature Rev Cancer 4 (2004) 505-518
14. Frassinetti S., Bronzetti G., Caltovuturo L., Cini M., and Croce C.D. The role of zinc in a life: a review. J Environ Pathol Toxicol Oncol 25 (2006) 597-610
15. Truong-Tran A.Q., Carter J., Ruffin R.E., and Zalewski P.D. The role of zinc in caspase activation and apoptotic cell death. Biometals 14 (2001) 315-330
16. Beyersmann D., and Haase H. Function of zinc in signaling, proliferation and differentiation of mammalian cells. Biometals 14 (2001) 331-341
17. Chimienti F., Seve M., Richard S., Mathieu J., and Favier A. Role of cellular zinc in programmed cell death: temporal relationship between zinc depletion, activation of caspases and cleavage of Sp family transcription factors. Biochem Pharmacol 62 (2001) 51-62
18. Prasad A.S. Zinc deficiency. Br Med J 326 (2003) 409-410
19. Hambidge M. Human zinc deficiency. J Nutr 130 (2000) 1344S-1349S
20. Liang J.Y., Liu Y.Y., Zou J., Franklin R.B., Costello L.C., and Feng P. Inhibitory effect of zinc on human prostatic carcinoma cell growth. Prostate 40 (1999) 200-207
21. Iguchi K., Hamatake M., Ishida R., et al. Induction of necrosis by zinc in prostate carcinoma cells and identification of proteins increased in association with this induction. Eur J Biochem 253 (1998) 766-770
22. Feng P., Li T.L., Guan Z.X., Franklin R.B., and Costello L.C. Effect of zinc on prostatic tumorigenecity in nude mice. Ann N Y Acad Sci 1010 (2003) 316-320
23. Fong L.Y., Nguyen V.T., and Farber J.L. Esophageal cancer prevention in zinc-deficient rats: rapid induction of apoptosis by replenishing zinc. J Natl Cancer Inst 93 (2001) 1525-1533
24. Jaiswal A.S., and Narayan S. Zinc stabilizes adenomatous polyposis coli (APC) protein levels and induces cell cycle arrest in colon cancer cells. J Cell Biochem 93 (2004) 345-357
25. Bae S.N., Kim J., Lee Y.S., Kim M.Y., Kim J.D., and Park L.O. Cytotoxic effect of zinc-citrate compound on choriocarcinoma cell lines. Placenta 28 (2007) 22-30
26. Bae S.N., Lee Y.S., Kim M.Y., Kim J.D., and Park L.O. Antiproliferative and apoptotic effects of zinc-citrate compound (CIZAR) on human epithelial ovarian cancer cell line, OVCAR-3. Gynecol Oncol 103 (2006) 127-136
27. Rudolf E., Rudolf K., and Cervinka M. Zinc induced apoptosis in HEP-2 cancer cells: the role of oxidative stress and mitochondria. Biofactors 23 (2005) 107-120
28. Wei H., Desouki M.M., Lin S., Xiao D., Franklin R.B., and Feng P. Differential expression of metallothioneins (MTs) 1, 2 and 3 in response to zinc treatment in human prostate normal and malignant cells and tissues. Mol Cancer 7 (2008) 1-7
29. Alley M.C., Scudiero D.A., Momks A., et al. Feasibility of drugs screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48 (1988) 589-601
30. Lowry O.H., Rosenbrough N.J., Farr A.L., and Randall R.J. Protein measurement with the folin phenol reagent. J Biol Chem 193 (1951) 256-275
31. Mawson C.A., and Fischer M.I. The occurrence of zinc in the human prostate gland. Can J Med Sci 30 (1952) 336-339
32. Mawson C.A., and Fischer M.I. Zinc and carbonic anhydrase in human semen. Biochem J 55 (1953) 696-700
33. Prasad A.S. Zinc deficiency in human subjects. Prog Clin Biol Res 129 (1983) 1-33
34. Prasad A.S. Clinical and biochemical manifestation zinc deficiency in human subjects. J Pharmacol 16 (1985) 344-352
35. Fair W.R., Couch J., and Wehner N. Prostatic antibacterial factor. Urology 7 (1976) 169-177
36. Costello L.C., and Franklin R.B. Aconitase activity, citrate oxidation, and zinc inhibition in rat ventral prostate. Enzyme 26 (1981) 281-287
37. Costello L.C., Liu Y., Franklin R.B., and Kennedy M.C. Zinc inhibition of mitochondrial aconitase and its importance in citrate metabolism of prostate epithelial cells. J Biol Chem 272 (1997) 28875-28881
38. Ishii K., Usui S., Sugimura Y., Yamamoto H., Yoshikawa K., and Hirano I. Inhibition of aminopeptidase N (AP-N) and urokinase-type plasminogen activator (UPA) by zinc suppresses the invasion activity in human urological cancer cells. Biol Pharm Bull 24 (2001) 226-230
39. Cardillo M.R., Monti S., Di Silvero F., Gentile V., Sciarpa F., and Toscano V. Insulin-like growth factor, IGF-I, IGF-II and IGF-type I receptor (IGF-IR) expression in prostate cancer. Anticancer Res 23 (2003) 38225-38235
40. waf can block cells at two points in the cell-cycle but does not interface with processive DNA-replication or stress-activated kinase. Oncogene 16 (1998) 431-441
41. Feng P., Liang J.Y., Li T.L., Guan Z.X., Zou J., and Franklin R. Zinc induces mitochondria apoptogenesis in prostate cells. Mol Urol 4 (2000) 822-826
42. Feng P., Li T.L., Guan Z.X., Franklin R.B., and Costello L.C. Direct effect of zinc on mitochondrial apoptogenesis in prostate cancer cell. Prostate 52 (2002) 311-318
43. Resnicoff M., Abraham D., Yutanawiboonchai W., et al. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res 5585 (1995) 2463-2469
44. Stewart C.E., and Rotwein P. Insulin-like growth factor-II is an autocrine survival factor for differentiating myoblasts. J Biol Chem 271 (1996) 11330-11338
45. Sell C., Baserga R., and Rubin R. Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis. Cancer Res 55 (1995) 303-306
46. Werner H., Karnieli E., Rauscher F.J., and LeRoith D. Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci. USA 93 (1996) 8318-8323
47. Rajah R., Valentinis B., and Cohen P. Insulin-like growth factor binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 272 (1997) 12181-12188
48. Baxter R.C. Signalling pathways involved in antiproliferative effects of IGFBP-3: a review. Mol Pathol 54 (1997) 145-148
49. Kaicer E., Blat C., and Harel L. IGF-I and IGF-binding proteins: stimulatory and inhibitory factors secreted by human prostatic adenocarcinoma cells. Growth Factors 4 (1991) 231-237
50. Angelloz-Nicoud P., and Binoux M. Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3). Endocrinol 136 (1995) 5485-5492
51. Velez-Yanguas M.C., Kalebic T., Maggi M., et al. 1 alpha, 25-dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531) modulation of insulin-like growth factor-binding protein-3 and induction of differentiation and growth arrest in a human osteosarcoma cell line. J Clin Endocrinol Metab. 8 (1996) 93-99
52. Tang X., and Shay N.F. Zinc has an insulin-like effect on glucose transport mediated by phosphoinositol-3-kinase and Akt in 3T3-4 fibroblast and adipocytes. J Nutr 131 (2001) 1414-1420
53. Fischer E.H. Cell signaling by protein tyrosine phosphorylation. Adv Enzyme Regul 39 (1999) 359-369
54. Haase H., and Maret W. Intracellular zinc fluctuations modulate protein tyrosine phosphatase activity in insulin/insulin-like growth factor-1 signaling. Exp Cell Res 29 (2003) 289-298
55. Provinciali M., Stefano G., and Fabris N. Dose-dependent opposite effect of zinc on apoptosis in mouse thymocytes. Int J Immunopharmacol 17 (1995) 735-744
56. Waters S.B., and Pessin J.E. Insulin receptor substrate 1 and 2 (IRS1 and IRS2): what a tangled web we weave. Trends Cell Bio 6 (1996) 1-4
57. Patti M.E., Sun X.J., Bruening J.C., Araki E., Lipes M.A., White M.F., and Kahn C.R. 4PS/insulin receptor substrate (IRS)-2 is the alternative substrate of the insulin receptor in IRS-1-deficient mice. J Biol Chem 270 (1995) 24670-24673
58. Argetsinger L.S., Hsu G.W., Meyers Jr. M.G., Billestrup N., White M.F., and Carter-Su C. Growth hormone, interferon-gamma, and leukemia inhibitory factor promoted tyrosyl phosphorylation of insulin receptor substrate-1. J Biol Chem 270 (1995) 14685-14692
59. Argetsinger L.S., Norstedt G., Billestrup N., White M.F., and Carter-Su C. Growth hormone, interferon-gamma, and leukemia inhibitory factor utilize insulin receptor substrate-2 in intracellular signaling. J Biol Chem 271 (1996) 29415-29421
60. Uddin S., Yenush L., Sun X.J., Sweet M.E., White M.F., and Platanias L.C. Interferon-alpha engages the insulin receptor substrate-1 to associate with the phosphatidylinositol 3′-kinase. J Biol Chem 270 (1995) 15938-15941
61. Singh R.P., Dhanalaksmi S., Tyagi A.K., Chan D.C.F., Agarwal C., and Agarwal R. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Res 62 (2002) 3061-3069
62. Foster F.M., Traer C.J., Abraham S.M., and Fry M.J. The phosphoinositide (PI) 3-kinase family. J Cell Sci 116 (2003) 3037-3040
63. Kasto R., Okkenhaug K., Ahmadi K., White S., Timms J., and Waterfield M.D. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 17 (2001) 615-675
64. Wu Y., Zu K., Warren M.A., Wallace P.K., and Ip C. Delineating the mechanism by which selenium deactivates Akt in prostate cancer cells. Mol Cancer Ther 5 (2006) 246-252
65. Jackson J.G., White M.F., and Yee D. Insulin receptor substrate-I is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells. J Biol Chem 273 (1998) 9994-10003
66. Baserga R. The IGF-I receptor in cancer research. Exp Cell Res 253 (1999) 1-6
67. Beyersmann D., and Hasse H. New approaches to antidepressant drug discovery beyond monoamines. Nat Rev Neurosci 7 (2006) 7-51
68. Putz T., Culig Z., Eder I.E., Nessler-Menardi C., Bartsch G., Grunicke H., Uberall F., and Klocker H. Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor-I and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. Cancer Res 59 (1999) 227-233